HOME >> MEDICINE >> NEWS
Researchers develop 'genetic blueprint' to predict response to esophageal cancer treatments

ANAHEIM - For the first time, researchers appear to be able to use a comprehensive panel of genetic variants to predict how a patient with esophageal cancer will respond to a spectrum of cancer treatments.

At the annual meeting of the American Association for Cancer Research (AACR), researchers from The University of Texas M. D. Anderson Cancer Center report that six different gene variants can predict an improved outcome in patients treated with two different chemotherapy drugs and/or with radiation therapy.

For example, the researchers say that a combination of several gene variants in patients treated with one type of chemotherapy (5-FU) more than doubled survival to 51 months, compared to 25 months in patients treated with the same drug who did not have these variants.

They say the findings represent a leap forward in the goal to provide tailored therapy to individual patients because it offers a genetic blueprint for gauging the potential effectiveness of all common esophageal cancer treatment, not just an analysis of how one or two "candidate" genes respond to a single treatment.

"Our data strongly suggest that combined pathway-based analysis may provide powerful clinical outcome predictors for esophageal cancer as well as for other cancers," says the study's lead author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology.

"This points to a promising new direction for cancer pharmacogenetics," she says. "Our hope is to have a gene chip one day that can analyze a patient's genetic makeup and help physicians predict response to a wide variety of therapeutic drugs before treatment even begins."

Esophageal cancer is highly aggressive; approximately 14,520 new esophageal cancer cases and 13,570 associated deaths are expected in 2005, according to the American Cancer Society. Almost half of new cases are diagnosed at an advanced stage, when the five-year survival rate is just 14 percent. Surgery
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
19-Apr-2005


Page: 1 2 3

Related medicine news :

1. Researchers suggest TB screening for all international adoptees
2. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
3. Researchers link metal ions to neurodegenerative disease
4. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
5. Researchers call for investigation into links between khat use and psychiatric disorders
6. Researchers use MRI to predict recovery after spinal cord injury
7. Researchers find deadly prescription drug effects 6 years before FDA
8. Researchers investigate impact of lifestyle on GI health
9. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
10. Researchers discover how antibiotic inhibits bacterial growth
11. Researchers urge caution in using ESAs for cancer-related anemia

Post Your Comments:
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
Cached News: